Published in AIDS on January 28, 2010
Parents and family members in the era of ART: evidence from Cambodia and Thailand. AIDS Care (2011) 0.82
Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya. AIDS Res Treat (2012) 0.78
Economic impact of HIV and antiretroviral therapy on education supply in high prevalence regions. PLoS One (2012) 0.78
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Technologies for global health. Lancet (2012) 5.05
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health (2009) 4.69
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS (2012) 3.50
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med (2013) 3.15
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health (2010) 2.92
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis (2005) 2.58
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.45
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc (2009) 2.31
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics (2007) 2.24
Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis (2011) 2.21
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev (2013) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS (2013) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo. Disasters (2003) 2.04
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health (2011) 2.02
Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health (2010) 2.00
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J (2005) 1.99
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (2004) 1.97
Income generating activities of people who inject drugs. Drug Alcohol Depend (2007) 1.95
HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med (2007) 1.94
Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. Int J Drug Policy (2007) 1.90
Operative mortality in resource-limited settings: the experience of Medecins Sans Frontieres in 13 countries. Arch Surg (2010) 1.89
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy (2008) 1.83
Role and outcomes of community health workers in HIV care in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2013) 1.82
Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.80
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr (2011) 1.74
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2012) 1.71
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA (2010) 1.67
Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc (2012) 1.66
Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ (2006) 1.64
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend (2005) 1.62
A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J (2007) 1.60
Drug treatment courts in Canada: an evidence-based review. HIV AIDS Policy Law Rev (2007) 1.59
Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health (2014) 1.58
Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa. J Acquir Immune Defic Syndr (2012) 1.58
Integrating research into routine service delivery in an antiretroviral treatment programme: lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda. Trop Med Int Health (2008) 1.58
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS (2006) 1.57
Elevated overdose mortality rates among First Nations individuals in a Canadian setting: a population-based analysis. Addiction (2010) 1.57
Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev (2008) 1.57
Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One (2011) 1.56
Surgical task shifting in Sub-Saharan Africa. PLoS Med (2009) 1.56
Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS (2011) 1.55
Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy (2011) 1.52
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med (2014) 1.51
Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS (2013) 1.51
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50